Most myeloma patients taking Tecvayli (teclistamab-cqyv) were alive and free from disease progression two years after starting treatment, according to a new analysis…
News
GYNECOLOGICAL CANCER
Study of gynecological cancer therapy moving fast in summer slowdown
A large, late-stage clinical trial testing an immunotherapy in people with gynecological cancers is recruiting participants ahead of schedule, even amid the typically slower…
A study linked high expression of the protein desmoglein-2 (DSG2) to lower survival in people with myeloma. Data suggest that high DSG2 expression is…
A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease progression and death among people…
The experimental anticancer therapy CR-001 was generally well tolerated in a first-in-human clinical trial that tested several doses in 11 people with acute myeloid leukemia…
Maintenance therapy for myeloma can be stopped after two years without raising the risk of disease progression or death, a new study shows. “For…
PANCREATIC CANCER
Vaccine to prevent pancreatic cancer passes first test in humans
An anticancer vaccine targeting a common genetic driver of pancreatic cancer was shown to be safe in an early clinical trial, with the results…
Dosing has begun in a Phase 3 clinical trial testing whether the antibody therapy Gamunex-C (immune globulin injection [human], 10% caprylate/chromatography purified) can help prevent…
GYNECOLOGICAL CANCER
Combination therapy completely clears ovarian cancer in lab mice
Combining immunotherapy with an experimental cell therapy from Ernexa Therapeutics completely eliminated ovarian cancer in two-thirds of mice in laboratory experiments. The new data,…
The U.S. Food and Drug Administration (FDA) has set a date for next year by which it will decide whether or not to approve a…
Recent Posts
- Finding unexpected meaning in the daily demands of caregiving
- Anticancer virus therapy rallies killer immune cells against myeloma
- Oral therapy wins approval in Europe for already-treated metastatic PDAC
- Tempest acquires rights to experimental myeloma treatment
- Medicare expansion of stem cell transplant coverage is a win